Who
Rahsaan Thompson
Chief Legal & Compliance
Company insider
Files Form 4 as: Chief Legal & Compliance, Zevra Therapeutics; Chief Legal Officer, Lyell Immunopharma; EVP and General Counsel, Gritstone bio.
In numbers
- Trades disclosed
- 33
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $2.2M
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 13 May 2020
- Last trade
- 14 Aug 2026
- Last filed
- 17 Aug 2026
Companies traded
Activity over time
1 Jun 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Aug 2026filed 17 Aug 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Sold | $475K42,666 at $11.13 | filing |
| 14 Aug 2026filed 17 Aug 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Sold | $475K42,666 at $11.13 | filing |
| 22 Jun 2026filed 23 Jun 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Sold | $438K34,557 at $12.68 | filing |
| 22 Jun 2026filed 23 Jun 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Sold | $438K34,557 at $12.68 | filing |
| 21 Jun 2026filed 23 Jun 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Code M | —66,667 | filing |
| 21 Jun 2026filed 23 Jun 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —66,667 at $0.00 | filing |
| 21 Jun 2026filed 23 Jun 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —66,667 at $0.00 | filing |
| 21 Jun 2026filed 23 Jun 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Code M | —66,667 | filing |
| 11 May 2026filed 13 May 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Sold | $20K1,794 at $11.30 | filing |
| 11 May 2026filed 13 May 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Sold | $20K1,794 at $11.30 | filing |
| 30 Jan 2026filed 2 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Code M | —11,333 | filing |
| 30 Jan 2026filed 2 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Sold | $36K4,080 at $8.83 | filing |
| 30 Jan 2026filed 2 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,333 at $0.00 | filing |
| 30 Jan 2026filed 2 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,333 at $0.00 | filing |
| 30 Jan 2026filed 2 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Code M | —11,333 | filing |
| 30 Jan 2026filed 2 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Sold | $36K4,080 at $8.83 | filing |
| 29 Jan 2026filed 2 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 29 Jan 2026filed 2 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 29 Jan 2026filed 2 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 29 Jan 2026filed 2 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
News
Contrasting Clene (NASDAQ:CLNN) and Zevra Therapeutics (NASDAQ:ZVRA)ZVRA · tickerreport.com · 22 Oct 2026
0 headlines in the last 90 days name Rahsaan Thompson; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.